Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

Ampersand Capital snaps up Vibalogics
July 2019
SHARING OPTIONS:

CUXHAVEN, Germany & WELLESLEY, Mass.—Ampersand Capital Partners will be acquiring Vibalogics GmbH, the companies announced recently. Vibalogics is a contract development and manufacturing organization (CDMO) that focuses on complex live biological products, offering process development, manufacturing, and fill and finish of products such as gene therapies, vaccines and oncolytic viral therapies. No specific details regarding the deal were disclosed, but the capital from the acquisition will support expansion of Vibalogics' capabilities to better answer industry demand.
 
David Anderson, general partner at Ampersand, said, “Vibalogics is a leading company in its field. Given the exciting developments within the complex virus market, this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company. We are looking forward to working with the team at Vibalogics to accelerate and continue its success in delivering cutting-edge therapies to patients in need.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.